Ligand Pharmaceuticals Inc. (LGND) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "LGND"
      ],
      "issuer_cik": "0000886163",
      "owner_cik": "0001950232",
      "accession_number": "0001950232-26-000003",
      "form_type": "4",
      "filing_date": "2026-10-06",
      "period_of_report": "2026-10-02",
      "issuer_name": "LIGAND PHARMACEUTICALS INC",
      "issuer_trading_symbol": "LGND",
      "owner_name": "Reardon Andrew",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CLO & Secretary",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-02",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 404,
      "transaction_price_per_share": 306.1834,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 32106,
      "transaction_value": 123698.09360000001,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."
        },
        {
          "id": "F5",
          "description": "The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ]
    },
    {
      "tickers": [
        "LGND"
      ],
      "issuer_cik": "0000886163",
      "owner_cik": "0001950232",
      "accession_number": "0001950232-26-000003",
      "form_type": "4",
      "filing_date": "2026-10-06",
      "period_of_report": "2026-10-02",
      "issuer_name": "LIGAND PHARMACEUTICALS INC",
      "issuer_trading_symbol": "LGND",
      "owner_name": "Reardon Andrew",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CLO & Secretary",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-02",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 1535,
      "transaction_price_per_share": 304.5154,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 32510,
      "transaction_value": 467431.139,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."
        },
        {
          "id": "F4",
          "description": "The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.